Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.

Illimis Therapeutics

Sanghoon Park

This department provides strategic direction and oversight for the organization.

Executive Leadership

This department focuses on identifying new growth opportunities and fostering strategic partnerships.

Business Development

This department oversees the initiation and progression of research and development projects.

Discovery Management

This department oversees organizational operations and strategic initiatives.

Management

This department oversees various operational functions and ensures effective leadership across the organization.

Illimis Therapeutics

Org chart

Teams

Executive Leadership

Business Development

Discovery Management

Management

Management Department

Offices

Illimis Therapeutics

Org chart

Teams

Executive Leadership

Business Development

Discovery Management

Management

Management Department

Offices

Related companies